维普期刊资源整合服务平台（V6.5）

64篇 您的检索式：作者名="KNOP FK"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus显示文摘	Aaboe K Knop FK Vilsboll T	2010	Diabetes Obes Metab2010，12，4：	1
2	Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities显示文摘	Lund A Knop FK Vilsboll T	2014	Eur J Intern Med2014，25，5：	1
3	Self-expanding metal stents for colonic obstruction:experiences from 104 procedures in a single center显示文摘	Meisner S Hensler M Knop FK et el		Diseases of the Colon & Rectum0，，：	1
4	Self-expanding metal stents for colonic obstruction:experiences from 104 procedures in a single center显示文摘	Meisner S Hensler M Knop FK	2004	Dis Colon Rectum2004，47，：	1
5	Do the actions of glucagon-like peptide-i on gastric emptying, appetite, and food intake involve release of amylin in humans? 显示文摘	Asmar M Bache M Knop FK	2010	J Clin Endocrinol Metab2010，95，：	1
6	Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes : differences and similar- ities显示文摘	Lund A Knop FK Vilsboll T	2014	Eur J Intern Ned2014，25，5：	1
7	Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes,exemplified by insulin degludec and liraglutide显示文摘	Vedtofte L Knop FK Vilsbo ll T	2015	Expert Rev Clin Pharmacol2015，8，3：	1
8	Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic poly- peptide in patients with end-stage renal disease 显示文摘	Idorn T Knop FK Jorgensen MB	2014	J Clin Endocrinol Metab2014，99，7：	1
9	Impaired regulation of the incretineffect in patients with type 2 diabetes 显示文摘	Bagger JI Knop FK Lund A	2011	J Clin Endocrinol Metab2011，96，3：	1
10	Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes : differences and simi- larities 显示文摘	Lund A Knop FK Vilsb:ll T	2014	Eur J Intern Med2014，25，5：	1
11	Mechanism of metabolic advantages after bariatric surgery显示文摘	Knop FK Taylor R	2013	Diabetes Care2013，36，：	1
12	Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity显示文摘	Knop FK Aaboe K Vilsboll T	2012	Diabetes Obes Metab2012，14，6：	1
13	Psoriasis is asso- ciated with type 2 diabetes显示文摘	Gyldenlove M Knop FK Vilsboll T	2013	Ugeskr Laeger2013，175，10：	1
14	Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses,but suppresses postprandial glucagon in obese subjects显示文摘	Knop FK Konings E Timmers S	2013	Diabet M ed2013，30，10：	1
15	Bile acid sequestrants:glucoselowering mechanisms and efficacy in type 2 diabetes显示文摘	Hansen M Sonne DP Knop FK	2014	Curr Diab Rep2014，14，5：	1
16	Treatment of type 2 dia betes with glucagon-like peptide 1 receptor agonists显示文摘	Hansen KB Knop FK Hoist JJ	2009	Int J Clin Pratt JT2009，63，8：	1
17	Reduced ineretin effeet in type 2 diabetes: cause or eonsequenee of the diabetic state?显示文摘	Knop FK Vilsb~ll T Hc~jberg PV	2007	Diabetes2007，56，8：	1
18	Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes different and similar- ities显示文摘	Lund A Knop FK Vilsboll T	2014	Eur J Intern Med2014，25，5：	1
19	Reduced incretin effect intype 2 diabetes : cause or consequence of the diabetic state 显示文摘	Knop FK Vilsb(pll T H(pjberg PV	2007	Diabetes2007，56，8：	1
20	Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity 显示文摘	Knop FK Aaboe K Vilsbll T	2012	Diabe- tes Obes Metab2012，14，6：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示